Novel agents to inhibit microbial virulence and pathogenicity. - Wikidata - wikimedia - TriplyDB

Novel agents to inhibit microbial virulence and pathogenicity.

Novel agents to inhibit microbial virulence and pathogenicity.

http://www.wikidata.org/entity/Q37780752

about

Targeting Bacterial Dsb Proteins for the Development of Anti-Virulence Agents Characterization of an Actin-targeting ADP-ribosyltransferase from Aeromonas hydrophila Establishment and validation of whole-cell based fluorescence assays to identify anti-mycobacterial compounds using the Acanthamoeba castellanii-Mycobacterium marinum host-pathogen system Targeting virulence not viability in the search for future antibacterials.Methicillin-resistant Staphylococcus aureus bacterial nitric-oxide synthase affects antibiotic sensitivity and skin abscess development.Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?Contribution of the A. baumannii A1S_0114 Gene to the Interaction with Eukaryotic Cells and Virulence Chlamydial biology and its associated virulence blockers.Developing new antibacterials through natural product research.Anti-virulence Strategies to Target Bacterial Infections.Workshop report: the 2012 antimicrobial agents in veterinary medicine: exploring the consequences of antimicrobial drug use: a 3-D approach.In Vitro Anti-inflammatory and Immunomodulatory Effects of Ciprofloxacin or Azithromycin in Staphylococcus aureus-Stimulated Murine Macrophages are Beneficial in the Presence of Cytochalasin D.Alanyl-phosphatidylglycerol and lysyl-phosphatidylglycerol are translocated by the same MprF flippases and have similar capacities to protect against the antibiotic daptomycin in Staphylococcus aureus.Antimicrobial activity of natural products from the flora of Northern Ontario, Canada.Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era.

P2860

Q26738760-3C0D4B27-4D6A-4E0F-B3C4-17C65C2D355B Q27672924-66FD531D-B6C9-4CD8-B655-F43D88F73595 Q28539402-63C5EEC2-C8D7-4211-9E79-4581D8871C24 Q35023691-93DD7B50-DD11-450B-8412-5443FCE1B955 Q36647337-35B91A5E-822F-4086-B37C-85B06E1307F8 Q36757725-52B222F6-CA19-4FF2-A679-D8295AB2E546 Q37733799-054C9031-7491-484F-B5E7-19ADCAA75CBA Q37847713-B6C4A58A-42D5-43C8-881F-3601240AF18B Q38088256-ACE2308F-AB2C-44D9-A457-813901D81158 Q38760476-31BFF947-63D3-4BD6-90E0-D2DE8EE5474E Q39261097-42083E7D-DA74-43D3-8A76-B8340BED3F37 Q41645682-C810510C-281B-4F6A-AEC0-B9C80213A7C0 Q41788681-62E21AF4-775A-4EA6-AB90-B081896F965C Q44856277-8019911A-4CCF-4134-A369-A76FFD2CAB34 Q53718587-888173B1-254D-4508-B3EE-F9F4CB577767

P2860

Novel agents to inhibit microbial virulence and pathogenicity.

http://www.wikidata.org/entity/Q37780752

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel agents to inhibit microbial virulence and pathogenicity.

@en

Novel agents to inhibit microbial virulence and pathogenicity.

@nl

type

label

Novel agents to inhibit microbial virulence and pathogenicity.

@en

Novel agents to inhibit microbial virulence and pathogenicity.

@nl

prefLabel

Novel agents to inhibit microbial virulence and pathogenicity.

@en

Novel agents to inhibit microbial virulence and pathogenicity.

@nl

P1433

Q37780752-EED49EDC-00F1-458E-BE1A-805C2FE8919D

P1476

Q37780752-F2E00425-9E23-4C17-A3FD-BF7E3FCA6C50

P2093

Q37780752-5A7D1466-07A0-4193-831A-D905CF648A1C

P2860

Q37780752-04BF19A1-BD54-412E-815B-3CF8755E9DDD

Q37780752-0BBFD87D-E233-49B6-8A71-8BF4B859AA3F

Q37780752-0D6C0346-32F2-4307-8F86-B6E0A87BE687

Q37780752-11630C8D-9722-46CA-AC90-87CED6098FD8

Q37780752-12440C27-E2E6-4C37-8494-DB61C122B95C

Q37780752-1E280174-BA49-4995-9021-B057EDE9F856

Q37780752-1E90029A-850D-46A6-9135-4B9E28375759

Q37780752-1EA08C10-DEDE-4BC5-A142-909FC8DAC406

Q37780752-1F89957C-9C69-46E3-AB90-92A8C27CC1AC

Q37780752-21851428-4E51-4417-BE7E-2A2D8002BC83

P304

Q37780752-079245F2-C26D-4C66-AA37-C102A97DEE80

P31

Q37780752-F884D266-2790-4B86-8802-F8FD49D002C4

P356

Q37780752-453BC4CC-E547-436E-8C8B-9EA0CB7797E4

P407

Q37780752-C4C13A99-BAC4-411C-A23B-3BCF8D5EB591

P433

Q37780752-AB147618-1B86-4851-9AC5-FE8DEC07DCA8

P478

Q37780752-A1797FA0-338C-41B7-A48C-32BFE2F5FAB0

P577

Q37780752-68882E5F-1A0A-419A-95AA-DB7D75FF8F80

P698

Q37780752-49A1CD7B-B6CE-44F1-8EFE-0ABF52356CAC

P356

13543776.2010.511176

P1433

Expert Opinion on Therapeutic Patents

P1476

Novel agents to inhibit microbial virulence and pathogenicity.

@en

P2093

Sonia Escaich

http://www.w3.org/2001/XMLSchema#string

P2860

Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria

A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence

Lipopolysaccharide endotoxins

Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weigh

Siderophore-based iron acquisition and pathogen control

Activation of Inhibitors by Sortase Triggers Irreversible Modification of the Active Site

Protein delivery into eukaryotic cells by type III secretion machines

Drugs for bad bugs: confronting the challenges of antibacterial discovery

Targeting type III secretion in Yersinia pestis.

Large-scale identification of genes required for full virulence of Staphylococcus aureus.

P304

1401-1418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543776.2010.511176

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20718591

http://www.w3.org/2001/XMLSchema#string